Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
02/02/2024 | Press release | Distributed by Public on 02/02/2024 12:18
Please select the service you want to use:
Smartlinks | CPKC - Canadian Pacific Kansas City Limited | Finance | Security Markets | Security Markets | Company News | Investment Funds | Securities Issuers | Railroad Companies | New York Stock Exchange (NYSE) | Frankfurt Stock Exchange | Sao Paulo Stock Exchange (B3) | Toronto Stock Exchange (TSX) | Bolsa Mexicana de Valores (BMV) | NYSE American | NYSE ARCA Equities | Cboe Canada | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | FINRA Alternative Display Facility (ADF) | Investors Exchange (IEX) | Omega ATS | Lynx ATS | Bolsa Institucional de Valores (BIVA) | CSE Pure Trading | Nasdaq BX | Nasdaq CX2 | Nasdaq CXC | Nasdaq Intermarket | Nasdaq PSX | NYSE Chicago | TSX Alpha Exchange
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact